HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Market Pulse Stocks News ETF News Crypto News

Madrigal Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Madrigal Pharmaceuticals, Inc.

Feb-11
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs MDGL GlobeNewswire
Feb-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Feb-02
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 MDGL GlobeNewswire
Jan-22
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Jan-21
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Jan-09
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor MDGL -7.58% GlobeNewswire
Dec-18
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL +8.56% MDGL GlobeNewswire
Dec-15
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference MDGL GlobeNewswire
Dec-04
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Nov-20
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Nov-17
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences MDGL GlobeNewswire
Nov-10
Madrigal Presents New Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis MDGL GlobeNewswire
Nov-06
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Nov-04
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates MDGL +7.83% GlobeNewswire
Oct-28
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025 MDGL GlobeNewswire
Oct-22
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 MDGL GlobeNewswire
Oct-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Oct-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Sep-18
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL +5.59% GlobeNewswire
Sep-04
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Sep-03
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference MDGL GlobeNewswire
Aug-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Aug-19
Madrigal Receives European Commission Approval for Rezdiffra (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis MDGL GlobeNewswire
Aug-11
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference MDGL GlobeNewswire
Aug-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Aug-05
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates MDGL +8.59% GlobeNewswire
Jul-30
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited MDGL GlobeNewswire
Jul-25
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 MDGL GlobeNewswire
Jul-22
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH MDGL -5.30% GlobeNewswire
Jul-16
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL +10.87% GlobeNewswire
Jul-16
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom) MDGL +10.87% GlobeNewswire
Jun-20
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis MDGL GlobeNewswire
Jun-17
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Jun-02
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference MDGL GlobeNewswire
May-10
Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis MDGL GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.